Epigenetic Dysregulation of Somatostatin Receptors ( SSTR ) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70635 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Neeraj Kumari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Epigenesis, Genetic, Neuroendocrine Tumors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT). However, 20%–30% of gastroenteropancreatic NETs and most poorly differentiated neuroendocrine carcinomas show insufficient SSTR expression, limiting therapeutic eligibility. Accumulating evidence indicates that reversible epigenetic mechanisms contribute substantially to SSTR loss, alongside tumor dedifferentiation, lineage‐state changes, and clonal evolution with DNA hypermethylation of the SSTR2 promoter representing a central event, complemented by chromatin remodeling and non‐coding RNA‐mediated regulation. Preclinical studies demonstrate that epigenetic therapies, including DNA methyltransferase and histone deacetylase inhibitors, can restore functional SSTR expression. Notably, the first‐in‐human LANTana trial provides clinical proof‐of‐concept that epigenetic priming with oral decitabine/cedazuridine can induce SSTR2 re‐expression and enable subsequent RPT in receptor‐negative tumors. This review synthesizes current knowledge of epigenetic regulation across all five SSTR subtypes (SSTR1–SSTR5), examines receptor silencing in neuroendocrine and non‐neuroendocrine malignancies, and critically evaluates the preclinical and clinical evidence supporting therapeutic strategies that target these mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Hematology and Oncology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Comprehensive Cancer Center Augsburg (CCCA), Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
ORCID-Profile: Neeraj Kumari, Michaela Kuhlen, Rainer Claus
Zitieren
APA
Kumari, N., Hoffmann, P., Reichl, L., Schmutz, M., Fischer, N., Dang, T. T. V., Ferrazzi, F., Johann, P., Kuhlen, M., Lapa, C., & Claus, R. (2026). Epigenetic Dysregulation of Somatostatin Receptors ( SSTR ) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies. International Journal of Cancer. https://doi.org/10.1002/ijc.70635
Vancouver
Kumari N, Hoffmann P, Reichl L, Schmutz M, Fischer N, Dang TTV, et al. Epigenetic Dysregulation of Somatostatin Receptors ( SSTR ) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies. International Journal of Cancer. 2026. doi:10.1002/ijc.70635
BibTeX
@article{Kumari2026,
author = {Kumari, Neeraj and Hoffmann, Pablo and Reichl, Laura and Schmutz, Maximilian and Fischer, Nina and Dang, Thi Tuong Vi and Ferrazzi, Fulvia and Johann, Pascal and Kuhlen, Michaela and Lapa, Constantin and Claus, Rainer},
title = {Epigenetic Dysregulation of Somatostatin Receptors ( SSTR ) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70635}
}
EUVIMED